Calyxt (CLXT) Misses Q3 EPS by 82c

Go back to Calyxt (CLXT) Misses Q3 EPS by 82c

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020

November 5, 2020 4:35 PM EST

Sponsored program at ASH 2020 Oral presentation of initial data for BALLI-01 clinical trial evaluating UCART22 product candidate in adult patients with R/R B-cell Acute Lymphoblastic Leukemia (B-ALL) Partnered programs at ASH 2020 UNIVERSAL abstract selected for oral presentation, ALLO-605 preclinical abstract selected for poster presentation, ALLO-316 preclinical abstract... More